These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 11060768)

  • 1. Anti-inflammatory therapies in sepsis and septic shock.
    Freeman BD; Natanson C
    Expert Opin Investig Drugs; 2000 Jul; 9(7):1651-63. PubMed ID: 11060768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing the efficacy of anti-inflammatory agents used in the treatment of sepsis.
    Minneci P; Deans K; Natanson C; Eichacker PQ
    Eur J Clin Microbiol Infect Dis; 2003 Jan; 22(1):1-9. PubMed ID: 12582737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapies for sepsis and septic shock.
    Oh HM
    Ann Acad Med Singap; 1998 Sep; 27(5):738-43. PubMed ID: 9919353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental and emerging therapies for sepsis and septic shock.
    Añel RL; Kumar A
    Expert Opin Investig Drugs; 2001 Aug; 10(8):1471-85. PubMed ID: 11772263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endotoxin as a drug target.
    Opal SM; Glück T
    Crit Care Med; 2003 Jan; 31(1 Suppl):S57-64. PubMed ID: 12544978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo therapeutics of β-thujaplicin on LPS-induced inflammation in macrophages and septic shock in mice.
    Shih MF; Chen LY; Tsai PJ; Cherng JY
    Int J Immunopathol Pharmacol; 2012; 25(1):39-48. PubMed ID: 22507316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis.
    Opal SM
    Int J Med Microbiol; 2007 Sep; 297(5):365-77. PubMed ID: 17452016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of endotoxic shock: glucocorticoids, lazaroids, nonsteroidals, others.
    Howe LM
    Vet Clin North Am Small Anim Pract; 1998 Mar; 28(2):249-67. PubMed ID: 9556848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis.
    Natanson C; Hoffman WD; Suffredini AF; Eichacker PQ; Danner RL
    Ann Intern Med; 1994 May; 120(9):771-83. PubMed ID: 8147551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel treatment strategy for sepsis and septic shock based on the interactions between prostanoids, nitric oxide, and 20-hydroxyeicosatetraenoic acid.
    Tunctan B; Korkmaz B; Sari AN; Kacan M; Unsal D; Serin MS; Buharalioglu CK; Sahan-Firat S; Schunck WH; Falck JR; Malik KU
    Antiinflamm Antiallergy Agents Med Chem; 2012; 11(2):121-50. PubMed ID: 23013331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoid administration in sepsis and septic shock: time for a paradigm change?
    Antonucci E; Fiaccadori E; Taccone FS; Vincent JL
    Minerva Anestesiol; 2014 Sep; 80(9):1058-62. PubMed ID: 24971687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroids for septic shock: back from the dead? (Pro).
    Balk RA
    Chest; 2003 May; 123(5 Suppl):490S-9S. PubMed ID: 12740234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide synthase inhibition as therapy for sepsis: a decade of promise.
    Cobb JP
    Surg Infect (Larchmt); 2001; 2(2):93-100; discussion 100-1. PubMed ID: 12594864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents in the therapy of endotoxic shock.
    Howe LM
    Expert Opin Investig Drugs; 2000 Jun; 9(6):1363-72. PubMed ID: 11060748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Corticotherapy in severe infectious states].
    Annane D; Sharshar T; Auriant I; Clair B; Raphael JC; Gajdos P
    Bull Acad Natl Med; 2000; 184(8):1631-40; discussion 1640-2. PubMed ID: 11471384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-sepsis protection of Xuebijing injection is mediated by differential regulation of pro- and anti-inflammatory Th17 and T regulatory cells in a murine model of polymicrobial sepsis.
    Chen X; Feng Y; Shen X; Pan G; Fan G; Gao X; Han J; Zhu Y
    J Ethnopharmacol; 2018 Jan; 211():358-365. PubMed ID: 28987599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathophysiology of sepsis and possible influence of statins].
    Fraunberger P; Drexel H; Walli AK
    Dtsch Med Wochenschr; 2010 Oct; 135(43):2128-32. PubMed ID: 20960384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death.
    Qiu P; Cui X; Barochia A; Li Y; Natanson C; Eichacker PQ
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1555-64. PubMed ID: 21961576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A scarlet pimpernel for the resolution of inflammation? The role of supra-therapeutic doses of cobalamin, in the treatment of systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic or traumatic shock.
    Wheatley C
    Med Hypotheses; 2006; 67(1):124-42. PubMed ID: 16545917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombin replacement in patients with sepsis and septic shock.
    Giudici D; Baudo F; Palareti G; Ravizza A; Ridolfi L; D' Angelo A
    Haematologica; 1999 May; 84(5):452-60. PubMed ID: 10329925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.